1. Volume 148, Issue 1, Pages 108-117 (January 2015)
Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation 
Michael Charlton, Edward Gane, Michael P. Manns, Robert S. Brown, Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, Richard Gilroy, Lewis Teperman, Andrew J. Muir, John G. McHutchison, William T. Symonds, Diana Brainard, Brian Kirby, Hadas Dvory-Sobol, Jill Denning, Sarah Arterburn, Didier Samuel, Xavier Forns, Norah A. Terrault 
Gastroenterology 
Volume 148, Issue 1, Pages (January 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
GS and sofosbuvir AUCtau in patients with SVR12 and relapse. (A) GS AUCtau in patients with SVR12 and relapse vs historical control, mean (SD). (B) Sofosbuvir AUCtau in patients with SVR12 and relapse vs historical control, mean (SD).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Ribavirin (RBV) mean daily dose and AUCtau in patients achieving SVR12 vs relapse. (A) RBV mean daily dose in patients achieving SVR12 vs relapse, mean (SD). (B) RBV AUCtau in patients achieving SVR12 vs relapse, mean (SD).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

4. Figure 3
Ribavirin (RBV) concentrations and hemoglobin levels by study visit, mean (SD).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions